Nicolas Girard

19PUBLICATIONS
219CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyMajor global burdens of disease
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Nov 06, 2026
PADL1NK-005 study design: a phase III trial of fetrastobart vedotin (Fetra-V) vs docetaxel in patients with previously treated tumor PD-L1-positive NSCLC.

|Sep 21, 2026
Subtype-Agnostic Biomarkers of Immunotherapy Response in Lung Cancer.

|Mar 03, 2026
Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.

Thomas Pierre Walter, Julien Mazieres, Josiane Otto

|Oct 27, 2025
Altered Thymopoiesis in Thymoma Is Associated with Defects in Negative Selection Machinery and Decreased Treg Abundance.

Clémence Basse, Alexandre Lanau, Camille Kergaravat

|Oct 14, 2025
Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial.

Charles M Rudin, Melissa L Johnson, Luis Paz-Ares

|May 08, 2025
Real-world treatment and outcomes for EGFR WT advanced/metastatic non-squamous non-small cell lung cancer: pooled analysis from project LUMINATE-101.

Nicolas Girard, Qingqing Xu, D Ross Camidge

Pageof 4

Frequent Collaborators

5 joint publications

Shun Lu

3 joint publications

Luis Paz-Ares

3 joint publications

Enriqueta Felip

2 joint publications

Clémence Basse